EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells

Cell Cycle

Volumn 5, Issue 23, 2006, Pages 2820-2826

  Garcia, Ruben ^a   Franklin, Richard A ^a   McCubrey, James A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Breast cancer; Drug resistance; EGF; EGFR; Motility

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CULTURE; CELL MOTILITY; DRUG RESISTANCE; GENE EXPRESSION; HUMAN; HUMAN CELL;

EID: 33845455068     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.23.3535     Document Type: Article

References (42)

1. Le XF, Pruefer F, Bast Jr RC. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signing pathways. Cell Cycle 2005; 4:87-95.
2. Citri AK, Bose S, Yarden Y. The Achilles heel of ErbB-2/HER2: Regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004; 3:51-60.
3. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, Stoter G, Nooter K. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response. Clin Cancer Res 2003; 9:827-36.
4. Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T, Katsumata N, Kang YK, Nishio K, Fujiwara Y. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 2006; 99:9-17.
5. Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L. Microtubule associated protein (MAP)-Tau: A novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle 2005; 4:1149-52.
6. Wells A. Tumor invasion: Role of growth factor-induced cell motility. Adv Cancer Res 2000; 78:31-101.
7. Sarkar S, Maceyka M, Hait NC, Paugh SW, Sankala H, Milstien S, Spiegel S. Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. FEBS Lett 2005; 579:5313-17.
8. Bogenrieder T, Herlyn M. Axis of evil: Molecular mechanisms of cancer metastasis. Oncogene 2003; 22:6524-36.
9. Furuta E, Bandyopadhyay S, Iiizumi M, Mohinta S, Zhan R, Watabe K. The role of tumor metastasis suppressors in cancers of breast and prostate. Front Biosci 2006; 11:2845-60.
10. Jessani N, Niessen S, Mueller BM, Cravatt BF. Breast cancer cell lines grown in vivo: What goes in isn't always the same as what comes out. Cell Cycle 2005; 4:253-55.
11. Seton-Rogers SE, Brugge JS. ErbB2 and TGF-beta: A cooperative role in mammary tumor progression? Cell Cycle 2004; 3:597-600.
12. Klein CA. Gene expression signatures, cancer cell evolution and metastatic progression. Cell Cycle 2004; 3:29-31.
13. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5:219-34.
14. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58.
15. Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 2005; 4:1201-15.
16. Hirschmann-Jax C, Foster AE, Wulf GG, Goodell MA, Brenner MK. A distinct "side population" of cells in human tumor cells: Implications for tumor biology and therapy. Cell Cycle 2005; 4:203-5.
17. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology/Haematology 1995; 19:183-232.
18. Bartlett JM, Going JJ, Mallon EA, Watters AD, Reeves JR, Stanton P, Richmond J, Donald B, Ferrier R, Cooke TG. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001; 195:422-28.
19. Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 2003; 12:362-7.
20. Shelton JG, Steelman LS, Abrams SL, Bertrand FE, Franklin RA, McMahon M, McCubrey JA. The epidermal growth factor receptor as a target for therapeutic intervention in numerous cancers-What's genetics got to do with it? Expert Opinion Therapeutic Targets 2005; 9:1009-30.
21. Settleman J. Inhibition of mutant EGF receptors by geftinib: Targeting an Achilles' heel of lung cancer. Cell Cycle 2004; 3:1496-97.
22. Haas-Kogan DA, Prados MD, Lamborn KR, Tihan T, Berger MS, Stokoe D. Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle 2005; 4:1369-72.
23. Shelton JG, Steelman LS, Abrams SL, White ER, Akula SM, Franklin RA, Bertrand FE, McMahon M, McCubrey JA. Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. Cell Cycle 2005; 4:822-30.
24. Shelton JG, Steelman LS, Abrams SL, White ER, Akula SM, Bertand FE, Franklin RA, McCubrey JA. Effects of endogenous epidermal growth factor receptor signaling on DNA signaling on DNA synthesis in a cytokine-dependent hematopoietic cell line. Cell Cycle 2005; 4:818-21.
25. Mizenina OA, Moasser MM. S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors. Cell Cycle 2004; 3:796-803.
26. Haber DA, Settleman J. Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class. Cell Cycle 2005; 4:1057-59.
27. Sako Y, Minoghchi S, Yanagida T. Single-molecule imaging of EGFR signaling on the surface of living cells. Nature Cell Biology 2000; 2:168-72.
28. Garcia R, Franklin RA, McCubrey JA. Cell death of MCF-7 human breast cancer cells induced by EGFR activation in the absence of other growth factors. Cell Cycle 2006; 5:1840-46.
29. Liu H, Radisky DC, Bissell MJ. Proliferation and polarity in breast cancer: Untying the Gordian knot. Cell Cycle 2005; 4:646-9.
30. Motti ML, De Marco C, Califano D, Fusco A, Viglietto G. Akt-dependent T198 phosphorylation of cyclin-dependent kinase inhibitor p27Kip1 in breast cancer. Cell Cycle 2004; 3:1074-80.
31. Weigelt B, van't Veer LJ. Hard-wired genotype in metastatic breast cancer. Cell Cycle 2004; 3:756-7.
32. Wang Q, Beck WT. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res 1998; 24:5762-9.
33. Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2001; 6:393-406.
34. Harari D, Yarden T. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000; 19:6102-14.
35. Kruger JS, Reddy KB. Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. Mol Cancer Res 2003; 1:801-9.
36. Wells A, Kassis J, Solava J, Turner T, Lauffenburger DA. Growth factor-induced cell motility in tumor invasion. Acta Oncol 2002; 41:124-30.
37. Nguyen DH, Webb DJ, Catling AD, Song Q, Dhakephalkar A, Weber MJ, Ravichandran KS, Gonias SL. Urokinase-type plasminogen activator stimulates the Ras/Extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells. J Biol Chem 2000; 275:19382-8.
38. Mahabeleshwar GH, Das R, Kundu GC. Tyrosine kinase, p56lck-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways. J Biol Chem 2004; 279:9733-42.
39. Honma N, Genda T, Matsuda Y, Yamagiwa S, Takamura M, Ichida T, Aoyagi Y. MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells. Lab Invest 2006; 86:687-96.
40. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006; 46:249-79.
41. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: How growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003; 9:447S-54S.
42. Hung MC, Lau YK. Basic science of HER-2/neu: A review. Semin Oncol 1999; 26:51-9.